Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

1.

The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism.

Fox J, Lowe SH, Conklin RL, Nemeth EF.

Endocrine. 1999 Apr;10(2):97-103.

PMID:
10451217
[PubMed - indexed for MEDLINE]
2.

Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism.

Wada M, Nagano N, Furuya Y, Chin J, Nemeth EF, Fox J.

Kidney Int. 2000 Jan;57(1):50-8.

PMID:
10620187
[PubMed - indexed for MEDLINE]
Free Article
3.

Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.

Mizobuchi M, Hatamura I, Ogata H, Saji F, Uda S, Shiizaki K, Sakaguchi T, Negi S, Kinugasa E, Koshikawa S, Akizawa T.

J Am Soc Nephrol. 2004 Oct;15(10):2579-87.

PMID:
15466262
[PubMed - indexed for MEDLINE]
Free Article
4.

Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats.

Chin J, Miller SC, Wada M, Nagano N, Nemeth EF, Fox J.

J Am Soc Nephrol. 2000 May;11(5):903-11.

PMID:
10770968
[PubMed - indexed for MEDLINE]
Free Article
5.

A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication.

Antonsen JE, Sherrard DJ, Andress DL.

Kidney Int. 1998 Jan;53(1):223-7.

PMID:
9453023
[PubMed - indexed for MEDLINE]
Free Article
6.

Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia.

Ishii H, Wada M, Furuya Y, Nagano N, Nemeth EF, Fox J.

Bone. 2000 Feb;26(2):175-82.

PMID:
10678413
[PubMed - indexed for MEDLINE]
7.

NPS R-568 halts or reverses osteitis fibrosa in uremic rats.

Wada M, Ishii H, Furuya Y, Fox J, Nemeth EF, Nagano N.

Kidney Int. 1998 Feb;53(2):448-53.

PMID:
9461105
[PubMed - indexed for MEDLINE]
Free Article
8.

NPS R-568: a type II calcimimetic compound that acts on parathyroid cell calcium receptor of rats to reduce plasma levels of parathyroid hormone and calcium.

Fox J, Lowe SH, Petty BA, Nemeth EF.

J Pharmacol Exp Ther. 1999 Aug;290(2):473-9.

PMID:
10411552
[PubMed - indexed for MEDLINE]
Free Article
9.

Calcimimetic compound NPS R-568 stimulates calcitonin secretion but selectively targets parathyroid gland Ca(2+) receptor in rats.

Fox J, Lowe SH, Conklin RL, Petty BA, Nemeth EF.

J Pharmacol Exp Ther. 1999 Aug;290(2):480-6.

PMID:
10411553
[PubMed - indexed for MEDLINE]
Free Article
10.

A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism.

Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW.

Kidney Int. 2000 Jul;58(1):436-45.

PMID:
10886592
[PubMed - indexed for MEDLINE]
Free Article
11.

The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor.

Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, Nagano N.

J Clin Invest. 1997 Dec 15;100(12):2977-83.

PMID:
9399943
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Prevention of uremic bone disease using calcimimetic compounds.

Olgaard K, Lewin E.

Annu Rev Med. 2001;52:203-20. Review.

PMID:
11160775
[PubMed - indexed for MEDLINE]
13.

Effect of the calcimimetic NPS R-467 on furosemide-induced nephrocalcinosis in the young rat.

Pattaragarn A, Fox J, Alon US.

Kidney Int. 2004 May;65(5):1684-9.

PMID:
15086907
[PubMed - indexed for MEDLINE]
14.

Calcimimetics normalize the phosphate-induced stimulation of PTH secretion in vivo and in vitro.

Almaden Y, Rodriguez-Ortiz ME, Canalejo A, Cañadillas S, Canalejo R, Martin D, Aguilera-Tejero E, Rodríguez M.

J Nephrol. 2009 Mar-Apr;22(2):281-8.

PMID:
19384847
[PubMed - indexed for MEDLINE]
15.

Zinc nutritional status modifies renal osteodystrophy in uremic rats.

Kimmel PL, Langman CB, Bognar B, Faugere MC, Chawla LS, Watkins DW, Malluche HH.

Clin Nephrol. 2001 Dec;56(6):445-58.

PMID:
11770796
[PubMed - indexed for MEDLINE]
16.

Reversibility of experimental secondary hyperparathyroidism.

Lewin E, Wang W, Olgaard K.

Kidney Int. 1997 Nov;52(5):1232-41.

PMID:
9350646
[PubMed - indexed for MEDLINE]
17.

Suppressive effect of calcium on parathyroid hormone release in adynamic renal osteodystrophy and secondary hyperparathyroidism.

Goodman WG, Veldhuis JD, Belin TR, Juppner H, Salusky IB.

Kidney Int. 1997 May;51(5):1590-5.

PMID:
9150477
[PubMed - indexed for MEDLINE]
20.

Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.

Henley C 3rd, Yang Y, Davis J, Lu JY, Morony S, Fan W, Florio M, Sun B, Shatzen E, Pretorius JK, Richards WG, St Jean DJ Jr, Fotsch C, Reagan JD.

J Pharmacol Exp Ther. 2011 Jun;337(3):681-91. doi: 10.1124/jpet.110.178681. Epub 2011 Mar 21.

PMID:
21422163
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk